Document is current
Any future updates will be listed below
-
Authors
Franssen, Stijn
Holster, Jessica J.
Jolissaint, Joshua S.
Nooijen, Lynn E.
Cercek, Andrea
D’Angelica, Michael I.
Homs, Marjolein Y. V.
Wei, Alice C.
Balachandran, Vinod P.
Drebin, Jeffrey A.
Harding, James J.
Kemeny, Nancy E.
Kingham, T. Peter
Klümpen, Heinz-Josef
Mostert, Bianca
Swijnenburg, Rutger-Jan
Soares, Kevin C.
Jarnagin, William R.
Groot Koerkamp, Bas https://orcid.org/0000-0003-1917-6973
- License Information
-
More Information
Article History
First Online: 31 October 2023
Disclosures
: James Harding has received research support, paid to his institution, from Bristol Myers Squibb, Boehringer Ingelheim, CytomX, Debiopharm, Eli Lilly, Genoscience, Incyte, Loxo @ Lilly, Novartis, Polaris, Pfizer, Zymeworks, and Yiviva; and consulting/advisory fees from Adaptimmune, AstraZeneca, Bristol Myers Squibb, Exelexis, Elevar, Eisai, Genoscience (uncompensated), Hepion, Imvax, Merck (DSMB) Medivir, QED, Tyra, and Zymeworks (uncompensated). Stijn Franssen, Jessica J. Holster, Joshua S. Jolissaint, Lynn E. Nooijen, Andrea Cercek, Michael I. D’Angelica, Marjolein Y.V. Homs, Alice C. Wei, Vinod P. Balachandran, Jeffrey A. Drebin, Nancy E. Kemeny, T. Peter Kingham, Heinz-Josef Klümpen, Bianca Mostert, Rutger-Jan Swijnenburg, Kevin C. Soares, William R. Jarnagin, and Bas Groot Koerkamp have no disclosures to declare in relation to this work.
